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Abstract
Background: Endothelin-1 (ET-1), a vasoconstrictive and 
pro-inflammatory peptide, is associated with several car-
diovascular risk factors and outcomes. We aimed to inves-
tigate the association of plasma ET-1 levels and renal func-
tion among young and healthy adults.
Methods: Individuals aged 25–41  years were enrolled in 
a population-based cohort study. Main exclusion criteria 
were established kidney disease, cardiovascular diseases, 
diabetes mellitus and a body mass index > 35 kg/m2. 
Fasting venous plasma samples were used to measure 
creatinine, cystatin C and ET-1. The estimated glomerular 
filtration rate (eGFR) was calculated using the creatinine 
based chronic kidney disease epidemiology collabora-
tion (CKD-EPI) formula. Multivariable regression models 
were constructed to assess interrelationships of plasma 
ET-1 with parameters of renal function.
Results: Median age of the 2139 participants was 37 years, 
47% males. Median creatinine and eGFR were 67 μmol/L 
and 112 mL/min/1.73 m2, respectively. Using quartile one 
as the reference group, the β-coefficients (95% confidence 
intervals [CIs]) for eGFR were 0.06 (− 1.22 to 1.35), − 0.66 
(− 1.95 to 0.62) and − 1.70 (− 3.01 to − 0.39) for quartiles 
2–4 (p-for-trend = 0.0056), respectively and β-coefficients 
(95% CIs) for cystatin C were 0.002 (− 0.01 to 0.02), 0.02 
(0.003–0.03) and 0.03 (0.01–0.04) for quartiles 2–4 (p-for-
trend < 0.0001), respectively. Using ET-1 as a continuous 
variable, the β-coefficient (95% CI) for eGFR per 1-unit 
increase was − 1.82 (− 3.19 to − 0.44, p = 0.0095) and 0.02 
(0.01–0.04, p = 0.0003) for cystatin C. Similar results were 
found between creatinine and ET-1 levels.
Conclusions: ET-1 levels are strongly associated with para-
meters of renal function among young and healthy adults, 
suggesting an important role of ET-1 and endothelial func-
tion in the regulation of kidney function.
Keywords: chronic kidney disease; endothelin-1; epidemi-
ology; glomerular filtration rate; population based; renal 
function.
Introduction
Chronic kidney disease (CKD) represents a growing public 
health burden, which comes along with aging societies 
and rising prevalence of cardiovascular diseases and dia-
betes [1–4]. CKD is a major cause of morbidity and mortal-
ity [4–6]. Consequently, early detection and prevention of 
CKD is of major importance [7].
Endothelin-1 (ET-1) is a 21-amino-acid, mainly 
endothelium-derived, peptide with vasoconstrictive, 
inflammatory and mitogenic properties [8–11]. Elevated 
ET-1 levels have been associated with hypertension, 
endothelial dysfunction and atherosclerotic diseases [9, 
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12–17]. Mostly experimental studies have also indicated 
that ET-1 is involved in regulation of renal function, but 
population-based studies on this issue are sparse [18–22].
Historically, the determination of plasma ET-1 levels 
has been time-consuming and cost-intensive. However, 
the advent of simple high-sensitivity assays lately enabled 
rapid determination plasma-derived ET-1 [23, 24]. These 
novel assays simplified the assessment of ET-1 levels 
and enable its determination in large population-based 
studies. In order to gain potential further insights into the 
role of the endothelin system in the regulation of kidney 
function, we evaluated the relationships of ET-1  with 
kidney parameters among young and healthy individuals 
without established kidney diseases.
Materials and methods
Study participants
The “Genetic and phenotypic determinants of blood pressure and 
other cardiovascular risk factors” (GAPP) study is an ongoing pro-
spective population-based cohort study among young and healthy 
adults in the Principality of Liechtenstein. The detailed study design 
has been previously published [25]. In brief, all inhabitants of the 
Principality of Liechtenstein aged between 25 and 41  years were 
invited to participate in this study. Our main exclusion criteria were 
established kidney disease, known cardiovascular disease or diabe-
tes mellitus, a body mass index (BMI) > 35 kg/m2 or any other severe 
illness. Each participant gave written informed consent and the 
Local Ethical Commission approved the study protocol. This study 
has been conducted by following the tenets of the Declaration of 
Helsinki.
Between 2010 and 2013, we enrolled 2170 individuals. For the 
purpose of this analysis, we excluded 30 individuals with missing 
information on either plasma ET-1, plasma creatinine, urinary albu-
min, blood pressure (BP) or physical activity. We also excluded one 
participant with a plasma creatinine level of 331.5 μmol/L. Thus, we 
included 2139 individuals in the present study.
Blood and urine sampling
Fasting venous blood and morning urinary samples were collected 
from every participant. After centrifugation, the samples were imme-
diately stored at – 80 °C. ET-1 was obtained from frozen EDTA plasma 
samples by using a high-sensitivity, single-molecule counting assay 
(Erenna® Immunoassay System, Singulex, Inc., Alameda, CA, USA) 
[24]. Our ET-1 assay’s limits of blank and quantification were 0.07 pg/mL 
and 0.33  pg/mL, respectively. Inter-assay coefficients of variation 
were 7% at an ET-1 concentration of 1.2 pg/mL and 6% at an ET-1 con-
centration of 1.8 pg/mL [24].
Plasma levels of creatinine, cystatin C, N-terminal pro brain-
natriuretic peptide (NT-pro-BNP), high-sensitivity C reactive protein 
(hs-CRP), low-density lipoprotein cholesterol (LDL-C), as well as 
urinary levels of creatinine and albumin were determined in fresh 
samples using a Roche Cobas 6000 analyzer (F. Hoffmann-La Roche 
Ltd., Switzerland). Urinary sodium, creatinine and albumin levels 
were also measured using a Roche Cobas 6000 analyzer. Glycated 
hemoglobin (HbA1c) was analyzed using high performance liquid 
chromatography (Bio-Rad D-10, Bio-Rad Laboratories AG, Switzer-
land) [25]. We calculated the estimated 24-h albuminuria and a uri-
nary albumin to creatinine ratio (UACR) of at least 30 mg/24 h was 
defined as an albuminuria, as previously described [26]. The glo-
merular filtration rate (eGFR) was estimated using the chronic kid-
ney disease epidemiology collaboration (CKD-EPI) formula based 
on plasma creatinine [27]. For the estimation of the 24  h urinary 
sodium excretion, we used morning spot urine samples and applied 
 Kawasaki’s formula [28]. Prediabetes/diabetes was defined as a 
HbA1c level > 5.7% [29].
Other study variables
Information about personal, medical, lifestyle and nutritional fac-
tors was collected using standardized questionnaires. The highest 
education level achieved was categorized into ‘high school’, ‘college’ 
or ‘university’ degree. Self-assessed smoking status was classified as 
current, former or never smoking. We dichotomized drinking hab-
its as drinkers versus non-drinkers. The individual physical activity 
questionnaire (IPAQ) was applied for the evaluation of the subjects’ 
physical activity level [25].
We obtained conventional BP measurements after at least 5 min 
of rest using a validated oscillometric device (Microlife BP3AG1, 
Microlife AG, Switzerland). The mean of the second and third meas-
urement was used for BP-related analyses. Hypertension was defined 
as a systolic BP  ≥  140 mmHg, a diastolic BP  ≥  90 mmHg or the intake 
of antihypertensive drugs. Body weight and height were measured in 
a standardized manner [25]. BMI was calculated by dividing weight 
in kilograms by height in meters squared. Bioelectrical impedance 
was used to estimate the body composition of all subjects using an 
established methodology and a validated device (BIA ego fit, 2010, 
Germany) [25].
Statistical analyses
We stratified the baseline characteristics by quartiles of ET-1. The dis-
tribution pattern of continuous variables was assessed using kurto-
sis, skewness and visual inspection of the histograms. The baseline 
characteristics of continuous variables were presented as medians 
(interquartile range) and compared using ANOVA or Kruskal-Wallis 
tests as appropriate. Categorical variables were compared using 
χ2-tests.
We used multivariable linear regression models to compare 
the β-coefficients of creatinine, cystatin C and the eGFR across 
quartiles of ET-1 and to adjust for potential confounders. All models 
were adjusted for a predefined set of covariates, including age, sex, 
BMI, LDL-C, HbA1c, systolic BP, hs-CRP, estimated urinary sodium 
excretion, estimated body water and muscle mass, physical activ-
ity, smoking status, alcohol consumption and education level. Since 
all associations were approximately linear, additional analyses were 
performed using ET-1 as a log-transformed continuous variable as the 
predictor of interest. Additionally, a logistic regression model was 
Bereitgestellt von | Inselspital Universitätsspital Bern
Angemeldet
Heruntergeladen am | 06.03.18 15:30
1204      Fischer et al.: Endothelin-1 and renal function
constructed to assess the relationship between ET-1 levels and UACR, 
using the same variables indicated above.
Stratified regression models were applied to assess the rela-
tionships between ET-1 and eGFR across pre-specified subgroups, 
including age, sex, BMI, prediabetes, hypertension and smoking, 
and formal differences were assessed using multiplicative interaction 
terms in the non-stratified models. Categorical variables were intro-
duced in all multivariable models using binary indicator variables. 
All statistical analyses were performed with SAS version 9.4 (SAS 
Institute, Inc., Cary, NC, USA). A p-value of < 0.05 was pre-specified 
to indicate statistical significance.
Results
Baseline demographics of the 2139 subjects according to 
quartiles of ET-1 are displayed in Table 1. Quartile-specific 
median ET-1 levels were 1.86, 2.33, 2.76, and 3.49 pg/mL. 
The median (interquartile range) eGFR was 112 (103–118) 
mL/min/1.73 m2. Being in a higher ET-1 quartile was signif-
icantly associated with male sex, and higher levels of BP, 
BMI, LDL-C, hs-CRP and estimated urinary sodium excre-
tion. Current smokers and individuals with higher physi-
cal activity levels had also higher ET-1 levels. There was 
a significant linear increase across ET-1 quartiles for cre-
atinine, cystatin C and eGFR (p < 0.0001, p < 0.0001 and 
p = 0.0043, respectively). We found nonlinear differences 
across ET-1 quartiles for body water (p = 0.011), alcohol 
intake (p = 0.006) and urinary albumin-to-creatinine ratio 
(p = 0.022).
Regression analyses for the association of creati-
nine, cystatin C, the eGFR and albuminuria with plasma 
ET-1 levels are displayed in Table 2. The significant rela-
tionships of ET-1 with creatinine, cystatin C and eGFR on 
univariable assessment persisted after adjustment for 
Table 1: Baseline characteristics according to quartiles of endothelin-1.
Total (n = 2139)
ET-1 range, pg/mL
Quartile 1 (n = 537)
0.11–2.12
Quartile 2 (n = 535)
2.12–2.54
Quartile 3 (n = 536)
2.54–3.06
Quartile 4 (n = 531)
≥ 3.06
p-Value
Age, years 35.9 (30.6–39.9) 37.0 (31.4–40.5) 36.3 (31.1–40.2) 37.3 (31.7–40.4) 0.076
Sex, male (%) 204 (38.0) 236 (44.1) 267 (49.8) 289 (54.4) < 0.0001
Highest education level (%) 0.51
 High school 55 (10.3) 41 (7.7) 41 (7.7) 38 (7.2)
 College 276 (51.9) 293 (55.3) 285 (53.6) 295 (56.2)
 University degree 201 (37.8) 196 (37.0) 206 (38.7) 192 (36.6)
Smoking (%) 0.0006
 Current 109 (20.3) 89 (16.6) 122 (22.8) 150 (28.3)
 Past 121 (22.5) 132 (24.7) 124 (23.1) 122 (23.0)
 Never 307 (57.2) 314 (58.7) 290 (54.1) 258 (48.7)
Physical activity, minutes 120 (60–300) 180 (60–360) 180 (60–360) 180 (60–420) 0.039
Alcohol intake, g/day 0.0 (0.0–1.4) 0.0 (0.0–1.7) 0.6 (0.0–2.0) 0.6 (0.0–1.7) 0.006
BMI, kg/m2 23.9 (21.7–26.7) 23.9 (21.5–27.0) 24.0 (21.8–26.6) 24.7 (22.1–27.9) 0.008
Muscle mass, % 34.8 (32.3–37.8) 35.1 (32.7–37.9) 35.6 (32.8–38.5) 35.1 (32.4–38.0) 0.14
Body water, % 54.0 (50.2–57.3) 54.5 (51.0–58.4) 55.3 (51.5–58.6) 54.3 (50.8–58.3) 0.011
Systolic BP, mmHg 118 (110–123) 120 (111–128) 120 (111–129) 122 (113–131) < 0.0001
Diastolic BP, mmHg 77 (72–83) 78 (72–84) 79 (72–84) 79 (73–86) 0.0017
Antihypertensive TRT (%) 8 (1.5) 11 (2.1) 6 (1.1) 10 (1.9) 0.63
NT-proBNP, pg/mL 36 (16–60) 36 (20–58) 31 (18–58) 34 (18–60) 0.46
Hs-CRP, mg/L 0.9 (0.5–1.8) 0.9 (0.5–1.7) 0.9 (0.5–1.8) 1.1 (0.5–2.3) 0.002
LDL-C, mmol/L 2.77 (2.28–3.34) 2.90 (2.33–3.50) 2.93 (2.39–3.50) 2.95 (2.41–3.63) 0.0021
Hemoglobin A1c, % 5.4 (5.1–5.6) 5.4 (5.2–5.7) 5.4 (5.1–5.6) 5.4 (5.2–5.7) 0.037
Prediabetes (%) 107 (19.9) 139 (26.0) 123 (23.0) 139 (26.2) 0.052
Creatinine, μmol/L 63.6 (55.7–74.3) 66.3 (57.4–75.1) 68.1 (57.5–77.8) 69.0 (60.1–79.6) < 0.0001
Cystatin C, mg/L 0.77 (0.70–0.85) 0.77 (0.69–0.86) 0.79 (0.71–0.87) 0.80 (0.73–0.88) < 0.0001
eGFR, mL/min/1.73 m2a 114 (105–119) 112 (106–118) 112 (103–118) 110 (101–118) 0.0043
UACR, mg/24 h 2.65 (1.54–4.97) 2.97 (1.81–5.79) 2.74 (1.62–4.94) 2.68 (1.58–5.03) 0.022
Urinary sodium excretion, g/24 hb 3.98 (3.21–4.84) 3.98 (3.17–4.93) 4.06 (3.36–5.11) 4.18 (3.30–5.22) 0.032
p-Values were based on Kruskal-Wallis tests or χ2-tests, as appropriate. Data are median (interquartile range) or number (percentage). BMI, 
body mass index; BP, blood pressure; TRT, treatment; NT-proBNP, N-terminal pro-brain natriuretic peptide; LDL-C, low-density lipoprotein 
cholesterol; Hs-CRP, high-sensitive C-reactive protein; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio. 
aThe estimated glomerular filtration rate was calculated by using the creatinine based CKD-EPI formula. bThe 24 h urinary sodium excretion 
was estimated by applying Kawasaki’s formula.
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multiple potential confounders. Compared to the lowest 
quartile, the eGFR of individuals in the highest quartile 
was significantly lower, as shown in Figure 1. On the other 
hand, we did not find a significant association between 
ET-1 levels and albuminuria, as shown in Table 2. There 
were no significant interactions for the association 
between ET-1 and the eGFR, as shown in Table 3.
Discussion
This study has several noteworthy findings. First, by 
applying a novel high-sensitivity assay, we were able to 
quantify plasma ET-1 levels in a large cohort of young 
and healthy adults at low cardiovascular risk. Second, 
our analyses revealed significant relationships of plasma 
ET-1  with creatinine, cystatin C and eGFR among these 
individuals without renal or atherosclerotic disease. By 
including a broad set of important clinical variables to 
our models, we further reduced the potential for residual 
confounding.
Earlier studies indicated that the endothelin system, 
particularly ET-1, directly influence the vasomotor func-
tion and thus renal blood flow, which consequently 
impacts renal function [30, 31]. It has also been shown that 
the endothelin system plays a key role in common patho-
physiological processes involved in most renal disorders, 
and ET-1, for example, directly promotes mesangial cell 
proliferation and glomerular sclerosis [21, 32]. Finally, 
smaller studies including patients with established renal 
disease have also shown that higher plasma concentra-
tions of ET-1 are inversely associated to measured GFR [33].
By highlighting a relationship between plasma 
ET-1 and renal parameters in individuals with a normal 
function (the median eGFR in this study was 112  mL/
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Figure 1: Relationship between plasma endothelin-1 and the esti-
mated glomerular filtration rate.
Data are β (95% confidence intervals) for ET-1 quartiles 2–4, respec-
tively using quartile 1 as the reference group.
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min/1.73 m2), we are confirming and expanding the exist-
ing, mostly experimental based knowledge about the 
endothelin-system to a population-based setting. Fur-
thermore, it is noteworthy that the relationship between 
ET-1 and the eGFR remained almost unaffected by adjust-
ment for hs-CRP and NT-pro-BNP, whereas the endothe-
lin system has been shown to trigger inflammation and 
natriuretic peptides synthesis, which in turn also influ-
ence the renal physiology [34, 35]. Hence, this might 
underscore the independent role of ET-1 in regulating the 
renal function. Our data actually suggest that ET-1 may be 
a sensitive marker of kidney blood flow and/or renal func-
tion even in adults with high-normal eGFR levels. Future 
studies should assess whether plasma-derived ET-1 might 
become a promising biomarker to estimate renal blood 
flow and function, and to identify individuals at risk for 
progression of kidney disease.
In this context, one needs to take in account that 
the prevalence of chronic kidney disease continuously 
increases with advancing age, affecting more than 20% of 
all individuals older than 60 years and 35% of those older 
than 70 years [1, 3, 4]. It is now also well-established that 
even early-stage renal failure adversely impacts general 
health and represents an independent cardiovascular risk 
factor [1, 3, 4]. Consequently, early recognition of adverse 
renal changes and ultimately prevention of a chronic 
renal condition, particularly cost-intensive and deadly 
end-stage renal disease (ESRD), are of utmost clinical 
importance.
In contrast to our study, earlier studies showed rela-
tionships between ET-1 and albuminuria [33, 36]. However, 
those studies mostly included either elderly individuals or 
patients with established renal disease, which may influ-
ence the described association there [37]. We presume that 
the earlier shown association between ET-1 and albumi-
nuria might be more important among individuals with 
advanced renal damage. Additionally, we only had a 
sample of 52 patients with albuminuria, which might limit 
the power to show an association. Moreover, this finding 
could also mean that the relationship between plasma 
ET-1 and renal parameters in young and healthy adults 
predominantly reflects renal perfusion and not tubular or 
glomerular damage.
Strengths of this population based-study are the large 
and well-characterized cohort of young and healthy indi-
viduals and the availability of measurable ET-1 levels in 
virtually all participants. We are aware of certain limita-
tions which apply to our study: First, the cross-sectional 
design of this study does not allow to draw causal infer-
ences; second, our study cohort included low risk and 
mainly white adults and the generalizability to other pop-
ulations remains unknown; third, we did neither directly 
Table 3: Subgroup analyses for the relationship between plasma endothelin-1 and the estimated glomerular filtration rate (eGFR).
n β (95% CI) p for interaction
Sex
 Male 984 − 3.10 (− 5.26 to − 0.93) 0.39
 Female 1123 − 1.18 (− 2.99 to 0.62)
Age, years
  ≥  35 1204 − 2.23 (− 3.97 to − 0.50) 0.81
 < 35 899 − 1.02 (− 3.40 to 1.35)
Prediabetes/diabetes
 Yes 498 − 3.39 (− 6.66 to − 0.12) 0.37
 No 1605 − 1.57 (− 3.10 to − 0.04)
BMI, kg/m2
  ≥  25 864 − 2.06 (− 4.05 to − 0.07) 0.89
 < 25 1239 − 1.61 (− 3.54 to 0.33)
Hypertension
 Yes 288 − 1.50 (− 5.11 to 2.10) 0.63
 No 1815 − 2.12 (− 3.61 to − 0.62)
Current smoking
 Yes 466 − 0.57 (− 3.39 to 2.25) 0.41
 No 1638 − 2.03 (− 3.61 to − 0.45)
The β-coefficients (95% confidence intervals) represent the increase of the estimated glomerular filtration rate (in mL/min/1.73 m2) per unit 
of log transformed endothelin-1 levels. All coefficients were adjusted for sex, age, body mass index, systolic blood pressure, low-density 
lipoprotein cholesterol, prediabetes/diabetes, high-sensitive C-reactive protein, N-terminal pro-brain natriuretic peptide, estimated urinary 
sodium excretion, estimated muscle mass, estimated total body water, education level, alcohol consumption, physical activity and current 
smoking.
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measure the renal function nor invasively estimate the 
endothelial function. However, the eGFR assessment with 
the CKD-EPI formula reflects a broadly validated tool for 
determination renal function, even among young individ-
uals [38–40]. In addition, it has been shown that levels of 
ET-1 are closely and directly linked to endothelial dysfunc-
tion and presence of atherosclerosis [24, 41].
Conclusions
In young and healthy adults, plasma ET-1 levels are signifi-
cantly associated with parameters of renal function. These 
findings suggest that ET-1  may play an important role in 
the regulation of renal physiology, especially regulation 
of renal blood flow. Future studies should assess the role 
of ET-1 in a clinical context and clarify whether this bio-
marker could improve risk stratification and identify indi-
viduals at risk for development of chronic renal disease.
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